Science VC
✓

Science VC

À PROPOS DE CE PODCAST 🔗

Science VC explores the intersection of deeptech startups and venture capital. Each episode features conversations with startup founders, venture capitalists, and industry experts. Discover their stories, lessons learned, and predictions for the future.  

Learn more about the challenges and opportunities of fundraising for venture-backed startups innovating in agtech, biotech, energy, foodtech, healthtech, and sustainability.

Technologie
Entreprenariat
Commercial
Animateurs :
Fréquence de mise à jour:
weekly
Durée audio moyenne:
57 minutes
Entretiens avec des invités
Podcast vidéo
Anglais
États-Unis
8 épisodes
depuis 27 février 2025
episodic
UtilisezAPIpour récupérer ce podcast dansJSON

DANS CE PODCAST 🔗

Modifier ces tags

DERNIER ÉPISODE 🔗

Why Not All Traction Is Equal | Aligning Latam’s Agtech Innovation with Industry Needs | The Role of LPs in Early VC Investing | Long-Term Thinking in Fundraising, with Galit Flasterstein, Managing Partner @ Danta Fund | Ep 8

Why Not All Traction Is Equal | Aligning Latam’s Agtech Innovation with Industry Needs | The Role of LPs in Early VC Investing | Long-Term Thinking in Fundraising, with Galit Flasterstein, Managing Partner @ Danta Fund | Ep 8

Biodiversity as an AdvantageGalit is a Managing Partner at Danta Fund, a VC firm that backs early-stage agritech startups in Latin America. Danta Fund has the mission of filling three main voids in Latin America: funding in early-stage agri-tech startups, mentorship to guide their founders, and con…
00:54:46
PARTAGER
ENREGISTRER

RECHERCHER LES ÉPISODES PASSÉS

Rechercher les épisodes précédents de Science VC.
Intégrez cette barre de recherche à votre site Web

ÉPISODES PRÉCÉDENTS

Unlocking Unsung Potential | LATAM Biotech’s Global Path | What Investors Really Look For | Avoiding Unforced Errors | Why Tulsa? | Building Cross-Border Deeptech Startups, with Michael Basch, GP and CEO @ Atento Capital | Ep 7

Unlocking Unsung Potential | LATAM Biotech’s Global Path | What Investors Really Look For | Avoiding Unforced Errors | Why Tulsa? | Building Cross-Border Deeptech Startups, with Michael Basch, GP and CEO @ Atento Capital | Ep 7

Why not Tulsa?Michael is the Founder, CEO, and General Partner of Atento Capital, a pre-seed and seed-stage VC firm focused on partnering with founders to build technology around healthcare, climate-tech, and business services.Topics in this episode0:00 Intro1:13 Michael’s Career Journey: From Foun…
00:52:53
PARTAGER
ENREGISTRER
Why No Idea Is Truly Unique | Leveraging Warm Intros and Mentorships | Communicating Urgency and Opportunities to VCs | Success Beyond Funding | Inside NYU’s Acceleration Program with Khoa Ma, Associate Director @ Endless Frontier Labs | Ep 6

Why No Idea Is Truly Unique | Leveraging Warm Intros and Mentorships | Communicating Urgency and Opportunities to VCs | Success Beyond Funding | Inside NYU’s Acceleration Program with Khoa Ma, Associate Director @ Endless Frontier Labs | Ep 6

Are there unique ideas anymore?Khoa Ma is an Associate Director at Endless Frontier Labs, a program at NYU Stern School of Business for early-stage science and technology startups. Topics in this episode0:00 Intro1:07 Khoa’s Career Path3:22 How Endless Frontier Labs Evaluates Startups8:45 What Gets…
01:03:13
PARTAGER
ENREGISTRER
Balancing Risk Across Two Industries | From Scientist to VC to Founder | Building Trust Among Co-founders | Protecting IP & Unlocking Markets | Fundraising Insights from Brazil with Larissa de Farias Viana, CEO @ APEXzymes | Ep 5

Balancing Risk Across Two Industries | From Scientist to VC to Founder | Building Trust Among Co-founders | Protecting IP & Unlocking Markets | Fundraising Insights from Brazil with Larissa de Farias Viana, CEO @ APEXzymes | Ep 5

Can a single innovation unlock multiple billion-dollar markets?Larissa is the CEO of APEXzymes, a Brazilian biotech startup that produces cost-effective enzymes for sustainable industrial applications. During our conversation, Larissa shares her journey from chemical engineering to venture capital …
00:57:22
PARTAGER
ENREGISTRER
The Business Case for Carbon Capture | A $200B Opportunity | Rethinking Industrial Supply Chains | Why You Need to Talk to Customers Early | Leveraging Non-Dilutive Capital with Alexander Ip, CEO @ CERT Systems | Ep 4

The Business Case for Carbon Capture | A $200B Opportunity | Rethinking Industrial Supply Chains | Why You Need to Talk to Customers Early | Leveraging Non-Dilutive Capital with Alexander Ip, CEO @ CERT Systems | Ep 4

Is it possible to transform carbon emissions into everyday products?Alex is the CEO of CERT Systems, a Canadian climatetech startup that converts CO2 emissions into high-value chemicals. In this episode, Alex shares his journey from the lab bench to raising non-dilutive capital. Topics in this epis…
00:58:04
PARTAGER
ENREGISTRER
Raising Capital in a Controversial Industry | Psychedelics & Mental Health | Building Investor Relationships | Showing Traction Before Regulatory Approval | Imposter Syndrome in LATAM Startups with Victoria Costa Paz, CEO @ EYWA | Ep 3

Raising Capital in a Controversial Industry | Psychedelics & Mental Health | Building Investor Relationships | Showing Traction Before Regulatory Approval | Imposter Syndrome in LATAM Startups with Victoria Costa Paz, CEO @ EYWA | Ep 3

There is a lot of stigma around psychedelics.Vicky is the CEO of EYWA, a biotech startup that produces molecules for mental health treatments. In this episode, we discussed the fundraising process for a startup working with psychedelics and the stigma surrounding the industry.Topics in this episode…
00:55:55
PARTAGER
ENREGISTRER
Disrupting Drug Discovery: Combining Quantum Electrochemistry and AI | Partnering with Oxford University | Why Second-Time Founders Have a Unique Edge | The Importance of Boldness and Patience with Diego Stone, CEO @ Qnity | Ep 2

Disrupting Drug Discovery: Combining Quantum Electrochemistry and AI | Partnering with Oxford University | Why Second-Time Founders Have a Unique Edge | The Importance of Boldness and Patience with Diego Stone, CEO @ Qnity | Ep 2

Investors don’t care how fancy your tech is.Diego is the CEO of Qnity, a pharmatech startup that uses quantum electrochemistry to develop devices for drug discovery and screening. In this episode, we discuss his lessons as a second-time founder and his insights on fundraising in the deeptech space.…
00:59:23
PARTAGER
ENREGISTRER
Picking the VCs You Approach | Protecting Your IP and Building Your Business Model | Creating Therapeutics for Animals Using Black Soldier Flies | Standing Out to Investors While Raising a Seed Round, with Gerardo Bluske, CBO @ ByBug | Ep 1

Picking the VCs You Approach | Protecting Your IP and Building Your Business Model | Creating Therapeutics for Animals Using Black Soldier Flies | Standing Out to Investors While Raising a Seed Round, with Gerardo Bluske, CBO @ ByBug | Ep 1

Why do founders have to be very picky about what VCs they approach?Gerardo Bluske is the Chief Business Officer of ByBug, a biotech startup that creates therapeutics for animals using black soldier flies. In this episode, Gerardo shares his insights about business development and fundraising.Topics…
00:56:05
PARTAGER
ENREGISTRER
Vous avez vu tous les épisodes de ce podcast
Avertissement: Le podcast et les illustrations intégrés sur cette page proviennent de JP Orlov, qui est la propriété de son propriétaire et n'est ni affilié ni approuvé par Listen Notes, Inc.
MOTEUR DE RECHERCHE DE PODCASTS
Vous pouvez utiliser notre site Web pour rechercher des podcasts3,826,039et des épisodes195,985,082par personnes, lieux ou sujets.
Investir dans le savoir offre le meilleur rendement, c'est pourquoi j'écoute des podcasts.  ‐ Benjamin "Llamacorn" Franklin

RECOMMANDATIONS

Utiliser API pour récupérer ce podcast